Xinjiang Medical Univ. VEGFR-2 compound B20

Xinjiang Medical Univ. VEGFR-2 compound B20: sourced facts only. name: "These results suggest that B20 is a potent VEGFR-2 and P-gp inhibitor with active potential for treating cisplatin-resistant cervical cancer." [PMID:38805911]; target: "These results suggest that B20 is a potent VEGFR-2 and P-gp inhibitor with active potential for treating cisplatin-resistant cervical cancer." [PMID:38805911]; developer: "The Xinjiang Key Laboratory of Natural Medicine Active Components and Drug Release Technology, College of Pharmacy, Xinjiang Medical University, Urumqi 830011, China." [PMID:38805911]; stage: "In the nude mouse HeLa/DDP cell xenograft tumor model, the inhibition rate of transplanted tumors was 39.2 % and 79.2 % when B20 was at 10 and 20 mg/kg, respectively." [PMID:38805911]